A User's Guide to the NINDS rt-PA Stroke Trial Database

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group

1995

Tissue plasminogen activator for acute ischemic stroke.

N Eng J Med

333

1581

1587

2. American Heart Association in Collaboraton with the International Liason Committee on Rususcitation

2000

Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 7: The era of reperfusion: Section 2: Acute stroke.

Circulation

102

suppl I

1204

1216

3. Quality Standards Subcommittee of the American Academy of Neurology, Practice Advisory

1996

Thrombolytic therapy for acute ischemic stroke: Summary statement.

Neurology

47

835

839

4. HoffmanJR

2001

Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative.

Can J Emerg Med

3

183

185

5. HoffmanJR

2000

Should physicians give tPA to patients with acute ischemic stroke? Against: And just what is the emperor of stroke wearing.

West J Med

173

149

150

6. HoffmanJR

2003

Tissue plasminogen activator (tPA) for acute ischaemic stroke: Why so much has been made of so little.

Med J Aust

179

333

334

7. MannJ

2002

Truths about the NINDS study: Setting the record straight.

West J Med

176

192

194

8. TrotterG

2002

Why were the benefits of tPA exaggerated? The role of interpretation bias.

West J Med

176

194

197

9. HaleyECLewandowskiCTilleyB

NINDS rt-PA Stroke Study Group

1997

Myths regarding the NINDS rt-PA Stroke Trial: Setting the record straight.

Ann Emerg Med

30

676

682

10. RobinsonDJ

2000

Should physicians give tPA to patients with acute ischemic stroke? For: Thrombolytics in stroke: Whose risk is it anyway.

West J Med

173

148

9

11. LattimoreSUChalelaJDavisLDeGrabaTEzzeddineM

2003

Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: The NINDS Suburban Hospital Stroke Center experience.

Stroke

34

e55

e57

12. LenzerJ

2002

Alteplase for stroke: Money and optimistic claims buttress the “brain attack” campaign.

BMJ

324

723

729

13. BroderickJLuMJacksonCPancioliATilleyB

2001

Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke.

Ann Neurol

49

736

744

14. BroderickJPLuMKothariRLevineSRLydenPD

2000

Finding the most powerful measures of t-PA's effectiveness in the NINDS t-PA Stroke Trial.

Stroke

31

2335

2341

15. BrottTLuMKothariRFaganSCFrankelM

1998

Hypertension and its treatment in the NINDS rt-PA Stroke Trial.

Stroke

29

1504

1509

16. BrunoALevineSRFrankelMRBrottTGLinY

2002

Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.

Neurology

59

669

674

17. FaganSCMorgensternLBPetittaAWardRETilleyBC

1998

Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke.

Neurology

50

883

890

18. FrankelMMorgensternLBKwiatkowskiTLuMTilleyBC

2000

Predicting prognosis after stroke: A placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.

Neurology

55

952

959

19. GrottaJWelchKMAFaganSLuMFrankelM

2001

Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial.

Stroke

32

661

668

20. KwiatkowskiTGLibmanRBFrankelMTilleyBCMorgensternLB

1999

Effects of tissue plasminogen activator for acute ischemic stroke at one year.

N Eng J Med

340

1781

1787

21. KwiatkowskiTLibmanRTilleyBCLewandowskiCGrottaJ

2005

The impact of imbalances in baseline stroke severity on outcome in the NINDS rt-PA Stroke Study.

Ann Emerg Med

45

377

384

22. LuMLydenPDBrottTGHamiltonSBroderickJP

2005

Beyond subgroup analysis: Improving the clinical interpretation of treatment effects in stroke research.

J Neurosci Methods

143

209

216

23. LuM

Tilley BC; the NINDS t-PA Stroke Trial Study Group

2001

Use of odds ratio or relative risk to measure a treatment effect in clinical trials with multiple correlated binary outcomes: Data from the NINDS t-PA Stroke Trial.

Stat Med

20

1891

1901

24. LuMTilleyBCLiS

1998

Issues on permutation tests: Applications in analysis of CT lesion volume in the NINDS T-PA Stroke Trial.

In

ASA Proceedings of the Biopharmaceutical Section

27

32

Alexandria (VA)

American Statistical Association

25. LydenLLuMJacksonCMarlerJKothariR

1999

Underlying structure of the NIH Stroke Scale: Results of factor analysis.

Stroke

30

2347

2354

26. LydenPLuMKwiatkowskiTFrankelMLevineS

2001

Thrombolysis in patients with transient neurologic deficits.

Neurology

57

2125

2128

27. LydenPLuMLevineSBrottTBroderickJ

2001

A modified National Institutes of Health Stroke Scale for use in stroke clinical trials.

Stroke

32

1310

1317

28. MarlerJRTilleyBCLuMBrottTGLydenPC

2000

Early stroke treatment associated with better outcome.

Neurology

55

1649

1655

29. PatelSCLevineSRTilleyBCGrottaJCLuM

2001

Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.

JAMA

286

2830

2838

30. TanneDLevineSRBreyRLLinHFaganSC

2003

Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial.

Neurology

61

1158

1159

31. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators

2004

Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA Stroke Trials.

Lancet

363

768

774

32. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group

1997

A systems approach to immediate evaluation and management of hyperacute stroke: Experience at eight centers and implications for community practice and patient care.

Stroke

28

1530

1540

33. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group

2000

Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography.

Stroke

31

2912

2919

34. The NINDS t-Pa Stroke Study Group

1997

Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Study.

Stroke

28

2119

2125

35. The NINDS t-Pa Stroke Study Group

1997

Intracerebral hemorrhage following intravenous t-PA therapy for ischemic stroke.

Stroke

28

2109

2118

36. The NINDS rt-PA Stroke Study Group

2005

Recombinant tissue plasminogen activator for minor strokes: The National Institute of Neurological Disorders and Stroke rt-PA Stroke study experience.

Ann Emerg Med

46

243

252

37. TilleyBCMarlerJGellerNLuMLeglerJ

1996

Use of a global test for multiple outcomes in stroke trials with application to the NINDS t-PA Stroke Trial.

Stroke

27

2136

2141

38. WooDBroderickJKothariRLuMBrottT

1999

Does National Institutes of Health Stroke Scale (NIHSS) favor left hemisphere stroke.

Stroke

30

2355

2359

39. IngallTJO'FallenWMAspludKGoldfrankLRHertzbergVS

2004

Findings from the reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial.

Stroke

35

2418

2424

40. SaverJLYafehB

2007

Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA Stroke Trials.

Stroke

38

414

416

41. HoffmanJRSchrigerDL

2007

Impact of treatment on individual patients in the NINDS Trial: A graphic representation based on change in NIHSS Score [abstract].

38th American College of Emergency Physicians Research Forum; 8–11 October 2007; Seattle, Washington, United States

42. IoannidisJPA

2005

Contradicted and initially stronger effects in highly cited clinical research.

JAMA

294

218

228

43. WardlawJMdel ZoppoGYamaguchiTBergeE

2006

Thrombolysis of acute ischemic stroke (Cochrane Review).

In

The Cochrane Library

Issue 3

Chichester (UK)

John Wiley and Sons

44. KatzanILFurlanAjLloydLEFrankJIHarperDL

2000

Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience.

JAMA

283

1151

1158

45. BravataDMKimeNConcatoJKrumholzHMBrassLM

2002

Thrombolysis for acute stroke in routine clinical practice.

Arch Intern Med

162

1994

2001